Johnson & Johnson (JNJ)vsNexgel Inc (NXGL)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
NXGL
Nexgel Inc
$0.29
+0.34%
HEALTHCARE · Cap: $3.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 811444% more annual revenue ($97.93B vs $12.07M). JNJ leads profitability with a 21.5% profit margin vs -51.3%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
NXGL
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Margin of Safety
+43.8%
Fair Value
$2.49
Current Price
$0.29
$2.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Revenue surging 27.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -80.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : NXGL
The strongest argument for NXGL centers on Price/Book, Revenue Growth. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NXGL
The primary concerns for NXGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.51 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NXGL is a growth play — different risk/reward profiles.
NXGL carries more volatility with a beta of 0.75 — expect wider price swings.
NXGL is growing revenue faster at 27.8% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 39/100), backed by strong 21.5% margins. NXGL offers better value entry with a 43.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Nexgel Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?